An exciting event took place place on October 18th in Portugal. SIP Portugal* was launched in an event held at the Calouste Gulbenkian Foundation, in Lisbon. The theme of the event was “Investigate, Evaluate, Educate, and Act“. Last March SIP Portugal prepared the joint statement that presents the common position of all those involved. This position paper proposes actions relevant to pain to be taken in two categories: employment and education.

This is only one of the many actions that the multidisciplinary group of SIP PT is developing this year as part of its mission: the promotion and design of policies and action strategies so that many of the key problems identified are reduced.

To know more about this joint statement and SIP PT, please visit the SIP PT dedicated page.

ABOUT SIP PORTUGAL

In June 2018 a group of multi-disciplinary healthcare professionals and a group of patient representatives met to identify relevant topics for SIP and launched the national SIP platform in Portugal. Both groups are now working together on their common priorities “Pain and Work” and “Awareness on Pain”.

ABOUT SIP

Healthcare professionals are represented by the Portuguese Pain Society (APED), Chapter of the European Pain Federation. This initiative is part of the broader European Campaign ”Societal Impact of Pain”, currently existing at European level and in 9 countries.

The “Societal Impact of Pain” (SIP) is an international platform created in 2009 as a joint initiative of the European Pain Federation EFIC® and the pharmaceutical company Grünenthal GmbH . The scientific framework of the SIP platform is under the responsibility of the European Pain Federation EFIC®. Co-operation partners for SIP are Pain Alliance Europe and Active Citizenship Network. The pharmaceutical company Grünenthal GmbH is responsible for funding and non-financial support.

 

 

Subscribe to the European Pain Federation Newsletter!

Don't worry, we will not spam you, you can unsubscribe at any time.

For more information on the transmission and use of your personal data, please refer to our privacy policy.Pr.

You have Successfully Subscribed!